---
document_datetime: 2023-09-21 19:46:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/depocyte-epar-procedural-steps-taken-authorisation_en.pdf
document_name: depocyte-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.3793193
conversion_datetime: 2025-12-31 04:54:10.67711
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The company, Pharmacia and Upjohn Ltd submitted on 5 October 1999 an application for Marketing Authorisation  to  the  European  Agency  for  the  Evaluation  of  Medicinal  Products  (EMEA)  for DepoCyte, through the centralised procedure. After agreement by the CPMP on 24 September 1997, confirmed  on  20  May  1999,  this  medicinal  product  has  been  referred  to  Part  B  of  the  Annex  to Council Regulation No (EEC) 2309/93 of 22 July 1993 as amended.  On 25 July 2000, the EMEA was notified  that  following  the  merger  of  Pharmacia  and  Upjohn  Ltd  with  Monsanto-Searle,  and  the consequent loss of marketing rights to the medicinal product, the applicant changed to Skye-Pharma Plc.

•

- During the March 2001 CPMP meeting, the remaining outstanding issues were addressed by the applicant during an oral explanation before the CPMP on 27 February 2001

The Rapporteur and Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. D. Jefferys (until March 2000) Dr. F. Rotblat Co-Rapporteur: R. Gaspar (until January 2000) Prof. J. Guimarães Morais (until January 2001) Prof. B. Silva Lima Licensing status: The product was not licensed in any country at the time of submission of the application. 2. Steps taken for the assessment of the product · The procedure started on 22 October 1999. · The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP  members  on  29 December  1999.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CPMP members on 6 January 2000. · During  the  meeting  on  15-17  February  2000  the  CPMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 17 February 2000. · The  applicant  submitted  the  responses  to  the  CPMP  consolidated  List  of  Questions  on  8 September 2000. · The summary report of the inspection carried out at the manufacturing site between 12 and 14 September 2000 of the manufacturer of the bulk product was issued on 9 October 2000 and an addendum to this report was issued on 21 March 2001. · The Rapporteur circulated the response assessment report on the applicant's responses to the List of Questions to all CPMP members on 26 October 2000. · During the CPMP meeting on 14-16 November 2000 a List of Outstanding Issues was adopted by the CPMP. · The applicant submitted the responses to the CPMP consolidated List of Outstanding Issues on 17 January 2001. The Rapporteur circulated the response assessment report on the applicant's responses to the List of Outstanding Issues to all CPMP members on 16 February 2001. Medicinal product no longer authorised

- During the March 2001 meeting the CPMP, in the light of the overall data submitted and the scientific discussion within the Committee, issued a positive opinion for granting a Marketing Authorisation to DepoCyte on 29 March 2001.
- The CPMP opinions were forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decisions on 11 July 2001.